A novel tumor-associated protein: clinical significance of serum levels in various clinical conditions with special reference to gynecological malignant diseases.
A novel tumor-associated protein (TAP), that was originally detected immunologically through the use of a monospecific antiserum against a placental antigen, was quantified by means of the rocket technique of Laurell. Four hundred and fifty-seven serum samples were obtained from healthy female subjects (55), and patients with leiomyomas (162), benign ovarian tumors (78), pelvic endometriosis (45), cervical cancer (73), endometrial cancer (18) and ovarian cancer (26), respectively. Statistical analysis showed that TAP exhibited the closest relationship in ovarian cancer patients in whom the appearance of TAP and its high level were most prominent. The present preliminary study suggests the clinical usefulness of this protein as a clinical adjunct for the management of ovarian cancer.
Nakai
M
M
Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan.
Kawauchi
H
H
Atsumi
M
M
Majima
T
T
Ishikawa
M
M
D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood*; D016889:Endometrial Neoplasms / Q000097:blood; D004715:Endometriosis / Q000097:blood / Q000601:surgery; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood*; D006801:Humans; D007044:Hysterectomy; D007889:Leiomyoma / Q000097:blood / Q000601:surgery; D010051:Ovarian Neoplasms / Q000097:blood; D010052:Ovariectomy; D010386:Pelvic Neoplasms / Q000097:blood; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D002583:Uterine Cervical Neoplasms / Q000097:blood
D000945:Antigens, Differentiation, T-Lymphocyte; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7